Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2021 | $6.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $6.00
Roth Capital reiterated coverage of InMed Pharmaceuticals with a rating of Buy and set a new price target of $11.50 from $12.00 previously
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-t
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional investor for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory markers, independent of amyloid beta or tau pathologyVancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of n
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G - InMed Pharmaceuticals Inc. (0001728328) (Subject)
SC 13G/A - InMed Pharmaceuticals Inc. (0001728328) (Subject)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)
S-1 - InMed Pharmaceuticals Inc. (0001728328) (Filer)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
8-K - InMed Pharmaceuticals Inc. (0001728328) (Filer)
VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces the Company has entered into a service contract (the "Contract") with Brio Financial Group ("Brio") to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022. Brio is a financial and management consulting group based in Bridgewater, New Jersey. The firm provid
VANCOUVER, British Columbia, Aug. 09, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is pleased to announce the appointment of Nicole Lemerond to its Board of Directors, effective immediately. Nicole Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. She has significant experience executing complex transactions, managing diligence processes, raising capital and structuring balance sheets. Throughout her career, Ms. Lemerond has worked with public
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announces Michael Woudenberg has been appointed Chief Operating Officer of the Company, overseeing all day-to-day operations. Mr. Woudenberg was previously Senior Vice President of Chemistry, Manufacturing and Controls. Mike has been an integral part of the executive team for the last four years, supporting multiple functions within the organisation. Prior to joining InMed, Mike had over 20 years of successful drug development, process engineering, GMP manufa
VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022. Conference Call & Webcast:Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern TimeRegistration Link: https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511Webcast Link: https://edge.media-server.com/mmc/p/cnawzqhu(Webcast replay available for 12 months) To access the call by phone, please go to the registration link, and you will be provided w
Completed acquisition of BayMedica, a rare cannabinoid manufacturing and commercialization company in the health and wellness sectorStrengthened IP with patent filing for use of rare cannabinoids for the treatment of neurodegenerative diseasesCommercial rollout of an additional rare cannabinoid, CBT- first of several rare cannabinoid launches planned for the first half of 2022Advanced the pharmaceutical drug development programs in EB, glaucoma and neurodegenerative diseases VANCOUVER, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the development, manufacturing and commercialization of rare cannabinoids,
VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021. Conference Call & Webcast*:Tuesday, February 15, 2022, at 11:00 AM Pacific Time, 02:00 PM Eastern TimeUS/CANADA Participant Toll-Free Dial-In Number: +1 (855) 605-1745US/CANADA Participant International Dial-In Number: +1 (914) 987-7959Conference ID: 8645175Webcast: https://edge.media-server.com/mmc/p/sa6ykfmv (*Webcast replay available